Yong Chen

Q: What is Yong Chen email address?

Email Yong Chen at yong.chen@astrazeneca.com. This email is the most updated Yong Chen email found in 2026.

Q: How to contact Yong Chen?

To contact Yong Chen send an email to yong.chen@astrazeneca.com. (updated on October 30, 2024)

Vice President (Bioanalysis & Biomarker) at Amador Bioscience | Furlong, Pennsylvania, United States

About Yong Chen

As the Vice President of Bioanalysis & Biomarker at Amador Bioscience, Yong Chen plays a pivotal role in advancing biopharmaceutical research and development. With over 20 years of extensive training in pharmaceutical science, molecular and cell biology, biochemistry, and neuroscience, Yong brings a wealth of knowledge and expertise to the organization. His commitment to minimizing uncertainty and maximizing the probability of successful outcomes is evident in his strategic approach to bioanalytical services.

At Amador Bioscience, Yong leads a talented team of experienced scientists in shaping the bioanalytical service strategy and portfolio. His focus on establishing comprehensive, high-quality bioanalytical capabilities and harmonized processes is crucial for the company’s growth and sustainability. Yong’s expertise in regulated testing, particularly within GxP lab operations, enables him to oversee critical aspects such as budgeting, capacity planning, and business development. His leadership ensures that the lab not only meets regulatory standards but also excels in delivering innovative solutions that drive the success of clients' projects.

Yong’s involvement in key projects spans various therapeutic areas, including neurology and diabetes, where he applies his deep understanding of biomarkers and protein-protein interactions. His proficiency in advanced techniques such as LC-MS, flow cytometry, and luciferase-based reporter gene assays enhances the lab's capabilities in delivering accurate and reliable bioanalytical results. By integrating biostatistics into the research process, Yong ensures that data-driven decisions are at the forefront of the company’s operations, ultimately contributing to the advancement of biopharmaceutical therapies that can transform patient outcomes.

Yong Chen Work